Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | NCEH1 | Q6PIU2 | 2/20 | 0.37 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 2/20 | 0.35 |
| ▸ | CTSB | P07858 | 2/20 | 0.35 |
| ▸ | CTSS | P25774 | 2/20 | 0.35 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 2/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | ALPL | P05186 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CETP | P11597 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14995850 | 0.78 | AR (0.42) | ALDH1A1GAANCEH1HCRTR2MEN1 | |
| SCHEMBL15005886 | 0.75 | NAMPT (0.39) | KDM4EALDH1A1GAA | |
| SCHEMBL3189598 | 0.73 | KDM4E (0.41) | KDM4EALDH1A1GAAKMT2AMAPT | |
| SCHEMBL15005922 | 0.73 | KDM4E (0.34) | KDM4EALDH1A1GAACTSL | |
| SCHEMBL4364572 | 0.72 | EGLN2 (0.42) | KDM4DCTSLCTSBCTSSEGLN2 | |
| SCHEMBL21605005 | 0.71 | GPR119 (0.37) | CTSLCTSBCTSSEGLN2DRD2 | |
| SCHEMBL30147842 | 0.71 | GPR119 (0.37) | CTSLCTSBCTSSEGLN2DRD2 | |
| SCHEMBL4081997 | 0.71 | KDM4E (0.39) | KDM4EALDH1A1GAACTSSMEN1 | |
| SCHEMBL4564052 | 0.70 | CTSS (0.41) | CTSLCTSBCTSSLMNA | |
| SCHEMBL26144386 | 0.70 | CETP (0.38) | KDM4DMAPTARLMNACETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2948453-B1 | PYRAZOLO[3,4-D]PYRIMIDINONE COMPOUNDS AS INHIBITORS OF THE P53/MDM2 INTERACTION | NOVARTIS AG (CH) | 2017-08-02 | — | — | EP | disclosed |
| EP-2948453-B1 | PYRAZOLO[3,4-D]PYRIMIDINONE COMPOUNDS AS INHIBITORS OF THE P53/MDM2 INTERACTION | NOVARTIS AG (CH) | 2017-08-02 | — | — | EP | disclosed |
| US-9556180-B2 | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction | NOVARTIS AG (CH) | 2017-01-31 | — | — | US | disclosed |
| US-9556180-B2 | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction | NOVARTIS AG (CH) | 2017-01-31 | — | — | US | disclosed |
| EP-2785717-B1 | PYRAZOLOPYRROLIDINE COMPOUNDS | NOVARTIS AG (CH) | 2016-01-13 | — | — | EP | disclosed |
| EP-2785717-B1 | PYRAZOLOPYRROLIDINE COMPOUNDS | NOVARTIS AG (CH) | 2016-01-13 | — | — | EP | disclosed |
| US-20150353563-A1 | PYRAZOLO[3,4-D]PYRIMIDINONE COMPOUNDS AS INHIBITORS OF THE P53/MDM2 INTERACTION | NOVARTIS PHARMA AG (CH) | 2015-12-10 | — | — | US | disclosed |
| US-20150353563-A1 | PYRAZOLO[3,4-D]PYRIMIDINONE COMPOUNDS AS INHIBITORS OF THE P53/MDM2 INTERACTION | NOVARTIS PHARMA AG (CH) | 2015-12-10 | — | — | US | disclosed |
| US-8969341-B2 | Pyrazolopyrrolidine compounds | NOVARTIS AG (CH) | 2015-03-03 | — | — | US | disclosed |
| US-8969341-B2 | Pyrazolopyrrolidine compounds | NOVARTIS AG (CH) | 2015-03-03 | — | — | US | disclosed |
| US-20140350010-A1 | Pyrazolopyrrolidine Compounds | NOVARTIS AG (CH) | 2014-11-27 | — | — | US | disclosed |
| US-20140350010-A1 | Pyrazolopyrrolidine Compounds | NOVARTIS AG (CH) | 2014-11-27 | — | — | US | disclosed |
| WO-2014115080-A1 | PYRAZOLO[3,4-D]PYRIMIDINONE COMPOUNDS AS INHIBITORS OF THE P53/MDM2 INTERACTION | NOVARTIS AG (CH) | 2014-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350010-A1 | Pyrazolopyrrolidine Compounds | MDM4, MDM2, TP53 | KDM4E 2322/4885ALDH1A1 2335/4885GAA 379/4885 |
| US-20150353563-A1 | PYRAZOLO[3,4-D]PYRIMIDINONE COMPOUNDS AS INHIBITORS OF THE P53/MDM2 INTERACTION | TP53, MDM4, MDM2 | KDM4E 2728/4885ALDH1A1 2135/4885GAA 1716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.